Publication Date
6-17-2020
Journal
JACC Case Reports
DOI
10.1016/j.jaccas.2020.04.039
PMID
34317411
PMCID
PMC8302111
PubMedCentral® Posted Date
6-17-2020
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
cardiovascular disease, hypercholesterolemia, secondary prevention
Abstract
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury. A kidney biopsy was performed and suggested acute tubular injury. The serum creatinine returned to baseline after discontinuation of alirocumab. (Level of Difficulty: Intermediate.)
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Cardiology Commons, Cardiovascular Diseases Commons, Medical Sciences Commons